Amos AF, McCarthy DJ,
Zimmet
P.The rising global burden of diabetes and
its complications: estimates and projections to the year 2010.
Diabet Med1997 ;14(suppl
5): S7-S85.
2.
British Diabetic Association.King's
Fund. Counting the cost: The real impact of non-insulin dependent diabetes,
1996 .
3.
Brun E., Nelson RG,
Bennett
PH et al. Diabetes duration and
cause-specific mortality in the Verona Diabetes Study. Diabetes
Care2000;23(8):1119-23.
4.
Haffner SM, Lehto S.,
Ronnemaa
T. et al. Mortality from coronary heart
disease in subjects with type 2 diabetes and in non-diabetic subjects with and without
prior myocardial infarction. N Engl J
Med1998;339:229-34.
5.
Balkau B., Shipley M.,
Jarrett
RJ et al. High blood glucose concentration
is a risk factor for mortality in middle-aged non diabetic men: 20-year follow-up in the
Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman
Study. Diabetes
Care1998;21:360-7.
6.
Roper NA, Bilous RW,
Kelly
WF et al. Cause-specific mortality in a
population of diabetics: South Tees Diabetic Mortality Study.
Diabetes Care2002;
25:43-8.
7.
Stratton IM, Adler AI,
Neil
HA et al. Association of glycaemia with
macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective
observational study.
BMJ2000;321:405.
8.
Adler AI, Stratton IM,
Neil
HA et al. Association of systolic blood
pressure with macrovascular and microvascular complications of type 2 diabetes. (UKPDS
36): prospective observational study .
BMJ2000;321:412.
9.
Haffner SM, Stem MP,
Hazuda
HP et al. Cardiovascular risk factors in
confirmed prediabetic individuals. Does the clock for CHD start ticking before the onset
of clinical
diabetes?JAMA1990;263:2893-8.
10.
Haffner SM, Mykkanen L.,
Festa
A. et al. Insulin-resistant prediabetic
subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects:
implications for preventing cardiovascular heart disease during the prediabetic
state.
Circulation2000;101:
975-80.
11.
Wolffenbuttel BHR , Gomis R.,
Squarrito
S. et al. Addition of low dose rosiglitazone
to SU therapy improves glycaemic control in type 2 diabetes patients.
Diabet Med2000;
17:40-7.
12.
Fonseca V., Rosenstock J.,
Patwardhan
R. et al. Effect of metformin and
rosiglitazone combination therapy in patients with type 2 diabetes.
JAMA2000;283:1695-702.
13.
Brunzell J. , Cohen B.,
Kreider
M. et al. Rosiglitazone favourably affects
LDL-C and HDL-C heterogeneity in type 2 diabetes.
Diabetes2001;50:A141.
14.
Freed M., Fuell D.,
Menci
L. et al. Effects of combination therapy
with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in
patients with type 2 diabetes .
Diabetologia2000;43(suppl
1):A267 Abs.
15.
Greenberg A. , Haffner S.,
Weston
W. et al. Rosiglitazone reduces C-reactive
protein, a marker of systemic inflammation, in type 2 diabetic patients.
Diabetologia2001;44(suppl
1):A222 Abs.
16.
Bakris G., Dole JF,
Porter
LE et al. Rosiglitazone improves blood
pressure in patients with type 2 diabetes mellitus.
Diabetes2000;49(suppl
1):A96 Abs.
17.
Carey DG, Galloway G.,
Dodrell
D. et al. Rosiglitazone reduces hepatic fat
and increases subcutaneous but not intra-abdominal fat depots.
Diabetologia2000;43(suppl
1):A68.
18.
Diabetes UK.Recommendations for the
management of diabetes in primary care. 2nd Ed.
October 2000.
19.
European Diabetes Policy
Group1999. A desktop guide to
type 2 diabetes mellitus. Diabet
Med1999;16:716-30.
